Prodrug design for brain delivery of small- and medium-sized neuropeptides

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)

Abstract

The blood-brain barrier (BBB) represents multiple barriers for drug delivery from the circulation. Peptides potentially useful to treat maladies of the brain are especially limited in their ability to cross the BBB due to several shortcomings. Specific delivery strategies have been conceived to outwit the BBB to target neuropeptides into the brain. It should be noted, however, that no unified method is possible for true brain-targeting of these fascinating biomolecules due to their structural features, properties, and intricate interplays among factors governing their entrance into and retention within the brain. In most brain-targeting prodrug approaches, a lipophilic and bioreversible moiety(ies) is covalently attached to the peptide that results in the complete loss of the innate biological activity of the parent peptide (prodrugs are inactive per definition) but significantly improves brain uptake and metabolic stability in the plasma and the interstitial fluid. Once the peptide prodrug has crossed the BBB, specific enzymes liberate the parent agent from its prodrug in the brain. To illustrate the applicability of the prodrug strategy for brain delivery of small neuropeptides, pGlu-Glu-Pro-NH 2, [Glu 2TRH], a thyrotropin-releasing hormone (TRH) analogue with a vast array of central activities, was chosen as an example. An ester prodrug provided significantly improved brain delivery compared to the unmodified parent peptide. The synthesis, in vitro and in vivo evaluations of this prodrug as specific examples are given for typical exploratory prodrug validation.

Original languageEnglish
Title of host publicationNeuropeptides
Subtitle of host publicationMethods and Protocols
EditorsAdalberto Merighi
Pages313-336
Number of pages24
DOIs
StatePublished - 24 Oct 2011

Publication series

NameMethods in Molecular Biology
Volume789
ISSN (Print)1064-3745

Fingerprint

Prodrugs
Neuropeptides
Brain
Blood-Brain Barrier
Peptides
Thyrotropin-Releasing Hormone
Extracellular Fluid
Esters
Enzymes

Keywords

  • Analeptic effect
  • Bioactivation
  • Blood-brain barrier
  • Immobilized artificial membrane chromatography
  • Lipophilicity
  • Neuropeptide
  • Neuropharmacology
  • Prodrug
  • Solid-phase peptide synthesis
  • Thyrotropin-releasing hormone analogue

Cite this

Prokai-Tatrai, K., & Prokai, L. (2011). Prodrug design for brain delivery of small- and medium-sized neuropeptides. In A. Merighi (Ed.), Neuropeptides: Methods and Protocols (pp. 313-336). (Methods in Molecular Biology; Vol. 789). https://doi.org/10.1007/978-1-61779-310-3_21
Prokai-Tatrai, Katalin ; Prokai, Laszlo. / Prodrug design for brain delivery of small- and medium-sized neuropeptides. Neuropeptides: Methods and Protocols. editor / Adalberto Merighi. 2011. pp. 313-336 (Methods in Molecular Biology).
@inbook{fc4fc72915404f4b987bd979f5c045c0,
title = "Prodrug design for brain delivery of small- and medium-sized neuropeptides",
abstract = "The blood-brain barrier (BBB) represents multiple barriers for drug delivery from the circulation. Peptides potentially useful to treat maladies of the brain are especially limited in their ability to cross the BBB due to several shortcomings. Specific delivery strategies have been conceived to outwit the BBB to target neuropeptides into the brain. It should be noted, however, that no unified method is possible for true brain-targeting of these fascinating biomolecules due to their structural features, properties, and intricate interplays among factors governing their entrance into and retention within the brain. In most brain-targeting prodrug approaches, a lipophilic and bioreversible moiety(ies) is covalently attached to the peptide that results in the complete loss of the innate biological activity of the parent peptide (prodrugs are inactive per definition) but significantly improves brain uptake and metabolic stability in the plasma and the interstitial fluid. Once the peptide prodrug has crossed the BBB, specific enzymes liberate the parent agent from its prodrug in the brain. To illustrate the applicability of the prodrug strategy for brain delivery of small neuropeptides, pGlu-Glu-Pro-NH 2, [Glu 2TRH], a thyrotropin-releasing hormone (TRH) analogue with a vast array of central activities, was chosen as an example. An ester prodrug provided significantly improved brain delivery compared to the unmodified parent peptide. The synthesis, in vitro and in vivo evaluations of this prodrug as specific examples are given for typical exploratory prodrug validation.",
keywords = "Analeptic effect, Bioactivation, Blood-brain barrier, Immobilized artificial membrane chromatography, Lipophilicity, Neuropeptide, Neuropharmacology, Prodrug, Solid-phase peptide synthesis, Thyrotropin-releasing hormone analogue",
author = "Katalin Prokai-Tatrai and Laszlo Prokai",
year = "2011",
month = "10",
day = "24",
doi = "10.1007/978-1-61779-310-3_21",
language = "English",
isbn = "9781617793097",
series = "Methods in Molecular Biology",
pages = "313--336",
editor = "Adalberto Merighi",
booktitle = "Neuropeptides",

}

Prokai-Tatrai, K & Prokai, L 2011, Prodrug design for brain delivery of small- and medium-sized neuropeptides. in A Merighi (ed.), Neuropeptides: Methods and Protocols. Methods in Molecular Biology, vol. 789, pp. 313-336. https://doi.org/10.1007/978-1-61779-310-3_21

Prodrug design for brain delivery of small- and medium-sized neuropeptides. / Prokai-Tatrai, Katalin; Prokai, Laszlo.

Neuropeptides: Methods and Protocols. ed. / Adalberto Merighi. 2011. p. 313-336 (Methods in Molecular Biology; Vol. 789).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Prodrug design for brain delivery of small- and medium-sized neuropeptides

AU - Prokai-Tatrai, Katalin

AU - Prokai, Laszlo

PY - 2011/10/24

Y1 - 2011/10/24

N2 - The blood-brain barrier (BBB) represents multiple barriers for drug delivery from the circulation. Peptides potentially useful to treat maladies of the brain are especially limited in their ability to cross the BBB due to several shortcomings. Specific delivery strategies have been conceived to outwit the BBB to target neuropeptides into the brain. It should be noted, however, that no unified method is possible for true brain-targeting of these fascinating biomolecules due to their structural features, properties, and intricate interplays among factors governing their entrance into and retention within the brain. In most brain-targeting prodrug approaches, a lipophilic and bioreversible moiety(ies) is covalently attached to the peptide that results in the complete loss of the innate biological activity of the parent peptide (prodrugs are inactive per definition) but significantly improves brain uptake and metabolic stability in the plasma and the interstitial fluid. Once the peptide prodrug has crossed the BBB, specific enzymes liberate the parent agent from its prodrug in the brain. To illustrate the applicability of the prodrug strategy for brain delivery of small neuropeptides, pGlu-Glu-Pro-NH 2, [Glu 2TRH], a thyrotropin-releasing hormone (TRH) analogue with a vast array of central activities, was chosen as an example. An ester prodrug provided significantly improved brain delivery compared to the unmodified parent peptide. The synthesis, in vitro and in vivo evaluations of this prodrug as specific examples are given for typical exploratory prodrug validation.

AB - The blood-brain barrier (BBB) represents multiple barriers for drug delivery from the circulation. Peptides potentially useful to treat maladies of the brain are especially limited in their ability to cross the BBB due to several shortcomings. Specific delivery strategies have been conceived to outwit the BBB to target neuropeptides into the brain. It should be noted, however, that no unified method is possible for true brain-targeting of these fascinating biomolecules due to their structural features, properties, and intricate interplays among factors governing their entrance into and retention within the brain. In most brain-targeting prodrug approaches, a lipophilic and bioreversible moiety(ies) is covalently attached to the peptide that results in the complete loss of the innate biological activity of the parent peptide (prodrugs are inactive per definition) but significantly improves brain uptake and metabolic stability in the plasma and the interstitial fluid. Once the peptide prodrug has crossed the BBB, specific enzymes liberate the parent agent from its prodrug in the brain. To illustrate the applicability of the prodrug strategy for brain delivery of small neuropeptides, pGlu-Glu-Pro-NH 2, [Glu 2TRH], a thyrotropin-releasing hormone (TRH) analogue with a vast array of central activities, was chosen as an example. An ester prodrug provided significantly improved brain delivery compared to the unmodified parent peptide. The synthesis, in vitro and in vivo evaluations of this prodrug as specific examples are given for typical exploratory prodrug validation.

KW - Analeptic effect

KW - Bioactivation

KW - Blood-brain barrier

KW - Immobilized artificial membrane chromatography

KW - Lipophilicity

KW - Neuropeptide

KW - Neuropharmacology

KW - Prodrug

KW - Solid-phase peptide synthesis

KW - Thyrotropin-releasing hormone analogue

UR - http://www.scopus.com/inward/record.url?scp=80054737357&partnerID=8YFLogxK

U2 - 10.1007/978-1-61779-310-3_21

DO - 10.1007/978-1-61779-310-3_21

M3 - Chapter

C2 - 21922418

AN - SCOPUS:80054737357

SN - 9781617793097

T3 - Methods in Molecular Biology

SP - 313

EP - 336

BT - Neuropeptides

A2 - Merighi, Adalberto

ER -

Prokai-Tatrai K, Prokai L. Prodrug design for brain delivery of small- and medium-sized neuropeptides. In Merighi A, editor, Neuropeptides: Methods and Protocols. 2011. p. 313-336. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-61779-310-3_21